Field Medical Advances Pulsed Field Ablation with $35M Series B
Deal News | Jul 02, 2025 | PR Newswire Cision Field Medical, Inc.
Field Medical, Inc., a medical technology company focused on next-generation pulsed field ablation (PFA) for heart arrhythmias, has successfully completed an oversubscribed Series B financing round, raising $35 million. This round was co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. The proceeds will expedite the regulatory readiness of Field Medical's FieldForce™ Ablation System, targeting ventricular tachycardia treatment (VT). The company is gearing up for its VERITAS pivotal approval study. Field Medical's CEO, Dr. Steven Mickelsen, highlighted the significant unmet clinical needs in ventricular tachycardia treatment, akin to the early stages of the atrial fibrillation market, emphasizing the clinical demand unmet by current technologies. Field Medical was recognized for its strong presence at the Heart Rhythm Society 2025 Meeting, where it showcased compelling pilot data. The company has cumulatively raised $75 million and aims to maintain its pioneering role in PFA innovations for complex arrhythmias. The Series B funds will also strengthen Field Medical's clinical and regulatory capabilities. As part of this accelerated growth phase, Field Medical's board is expanding, reflecting the momentum behind the company's clinical outcomes and solid business fundamentals.
Sectors
- Healthcare
- Medical Devices
Geography
- United States – Field Medical is based in Cardiff-by-the-Sea, California, and the investment involves U.S.-based private equity firms.
Industry
- Healthcare – The article focuses on Field Medical, a company developing a medical device for heart arrhythmias treatment, which falls under the healthcare sector.
- Medical Devices – Field Medical's core product is the FieldForce™ Ablation System, a next-generation PFA system for cardiac disorders, categorizing the company in the medical devices industry.
Financials
- $35 million – The total amount raised in Field Medical's oversubscribed Series B financing round.
- $75 million – The cumulative funds raised by Field Medical to date, indicating its financing trajectory.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Field Medical, Inc. | Target Company | Company | A medical technology company redefining heart ablation with its FieldForce™ Pulsed Field Ablation platform. |
| BioStar Capital | Lead Investor | Company | A private equity firm focused on healthcare investments, co-leading the Series B financing round. |
| Cue Growth | Lead Investor | Company | A growth-stage investment firm co-leading the Series B financing for Field Medical. |
| Dr. Steven Mickelsen | CEO | Person | Founder and CEO of Field Medical, spearheading innovation in pulsed field ablation technology. |
| Louis Cannon | Founder and Senior Managing Director of BioStar Capital | Person | Key figure supporting Field Medical's development initiative. |
| Oskar Dadason | CFO | Person | Chief Financial Officer of Field Medical, involved in strategic financing. |
| Mark Wisniewski | Board Chairman | Person | CFO of Enterra Medical, leading Field Medical's board through its next growth phase. |
| Marlou Janssen | Board Member | Person | Experienced executive and board member in medical technology. |
| Alexei Mlodinow | Board Member | Person | Serial entrepreneur and investor with success in medical technology innovations. |
| Ben Cannon | Founding Partner | Person | Founding Partner at Cue Growth, providing investment and scaling expertise. |